Investor Presentaiton

ENHERTU DESTINY-Breast06/08 studies ■DESTINY-Breast06 Ph3 study design Chemo naive HR+/HER2 low advanced or metastatic BC randomize 1:1 N = 850 ENHERTUⓇ Investigator's choice of chemo Endpoints: PFS, etc. Part 2 dose expansion ■DESTINY-Breast08 Ph1b study design Part 1 dose finding ENHERTU® + capecitabine ENHERTU® + durvalumab + paclitaxel HR+/HR- HER2 low ENHERTU® + capivasertib advanced or metastatic BC ENHERTU® + anastrozole N = 182 Endpoints: safety, efficacy, etc. BC: breast cancer, PFS: progression free survival ENHERTU® + fulvestrant Daiichi-Sankyo 21

View entire presentation